A low standard for granting patents can mean lengthy delays generic medicine availability. In one case this is shown to have cost taxpayers almost $A3 billion extra in Pharmaceutical Benefits Scheme outlays. A solution is to grant patents only for inventions that embody a significant increase in what is known. The cost of undeserved patents … Continue reading HAZEL MOIR. Evergreening of patents and the cost of pharmaceuticals.… Continue reading »